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Abstract: MYC is a target of the Wnt signalling pathway and governs numerous cellular and develop-
mental programmes hijacked in cancers. The amplification of MYC is a frequently occurring genetic
alteration in cancer genomes, and this transcription factor is implicated in metabolic reprogramming,
cell death, and angiogenesis in cancers. In this review, we analyse MYC gene networks in solid can-
cers. We investigate the interaction of MYC with long non-coding RNAs (lncRNAs). Furthermore, we
investigate the role of MYC regulatory networks in inducing changes to cellular processes, including
autophagy and mitophagy. Finally, we review the interaction and mutual regulation between MYC
and lncRNAs, and autophagic processes and analyse these networks as unexplored areas of targeting
and manipulation for therapeutic gain in MYC-driven malignancies.
Keywords: MYC; gene regulatory networks (GRNs); autophagy; lncRNAs
1. Introduction to MYC Transcription Factors and Their Roles in Cancer
The MYC family of proteins are basic helix-loop-helix leucine zipper (bHLHZip) tran-
scription factors (TFs) under tight transcriptional regulation. The MYC family includes
c-MYC (MYC), the first member identified in humans; MYCL; and MYCN [1], encoded
by c-MYC, L-MYC, and N-MYC (MYCN) genes, respectively [2]. MYC TFs can be trans-
activated by forming heterodimers with their partner protein, MAX, which then bind to
E-box motifs and, in association with the transcription machinery, trigger the regulation of
proliferation, metabolism, differentiation, cell cycle, apoptosis, DNA damage, angiogenesis,
protein synthesis, and mitochondrial function [3–5]. However, the low specificity of MYC
binding to E-box motifs can lead to the activation of alternative pathways and changes to
metabolic states [3–5]. Furthermore, MYC sits at the crossroads of numerous signalling
pathways where it can act as an early response mediator, and precise regulation of MYC
expression is critical for maintaining the balance between proliferative and differentiated
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cellular states [6]. MYC TFs are downstream of the Wnt signalling pathway and can be aber-
rantly expressed due to mutations in β-catenin and APC and modulation by non-coding
RNAs [7,8]. MYC expression is also dependent on other signalling pathways, including
PI3K/AKT/mTOR, Notch, TGF-β/SMADs, and growth factor-induced pathways [9–11].
In Figure 1, we highlighted the roles of Wnt, EGF, and TGF-β signalling pathways in
MYC regulation.
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Figure 1. The effects of three signalling pathways converging on MYC activation or repression.
A Wnt ligand binds to its receptor frizzled, preventing the phosphorylation of β-catenin by GSK3β
and its subsequent degradation. β-catenin accumulates in the nucleus and, in association with T-cell
factor/ lymphoid enhancer factor (TCF/LEF), activates Wnt signalling target genes, including MYC.
The positive input of growth and survival factors including EGF and its downstream mediators,
including MEK/MAPK/PI3K/AKT on MYC activation, while TGF-β signalling via SMADs can
sup ress MYC activity. MYC can form a heterodimer with MAX and can govern cell proliferation,
apoptosis, and metabolism.
MYC TFs are expressed in normal embryogenesis and play integral roles in influencing
normal developmental processes, such as brain development, including the cerebellum [12].
Furthermore, MYC inactivation may be a prerequisite for terminal differentiation, lineage
commitment, and cellular quiescence [13,14]. For instance, in haematopoietic progenitor
cells and skin stem cells, MYC can induce terminal differentiation and lineage commit-
ment [15,16].
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In cancers, however, MYC has also been shown to interact with other oncogenes, such
as RAS, in numerous cancers [17]. MYC activation can, when in association with other
mutagenic events, drive tumourigenesis. For instance, MYC expression driven by different
enhancers, in association with other mutations, led to leukaemia formation in various
B-cell developmental stages [8]. Moreover, alterations to MYC expression and function are
found in multiple malignancies, including cancers of the central and peripheral nervous
system such as glioblastoma multiforme, and neuroblastoma (NB) [18,19]. In many of
these cancers, MYC hijacks cellular and molecular programmes through an extensive
network of target genes, effectors, regulators, and signalling pathways. MYC has also
been implicated in the reprogramming of metabolic states and in promoting angiogenesis,
aggressive behaviour, and metastasis in cancers [20–23]. Table 1 shows examples of genes
associated with MYC TFs in a panel of cancers.
Table 1. Examples of MYC-associated partners, upstream mediators, or target genes and the malig-
nancies in which they have been identified.
Cancer Type
Examples of MYCN/MYC/MYCL-Associated Binding
Partners, Upstream Regulators, Effectors, and Target
Genes and Their Signalling Pathways
Prostate cancer Co-occupation with AR at FOXA1 and HOXB13 loci [24]
Pancreatic ductal adenocarcinoma KRAS and YAP [25]
Medulloblastoma SOX2 [26]
Neuroblastoma Wnt/ β-catenin, mir-204 [27,28]
Colorectal cancer Wnt-APC, CAD, UMPS, and CTPS [7]
Rhabdomyosarcoma PAX3-FOXO1 [29]
Non-small cell lung cancer KRAS, IL-23, and CCL9 [30,31]
In addition to MYC TFs’ roles in cell proliferation, metabolism, and angiogenesis,
these TFs may also be involved in lineage plasticity in cancers. Cell plasticity is defined
as the ability of a cell to alter its phenotype without genetic mutation in response to
environmental factors. It is considered an emerging mechanism of tumour evolution and
treatment resistance in cancers [24]. For instance, MYCN-driven, castration-dependent
prostate cancer may progress towards a neuroendocrine fate through lineage plasticity and
epigenetic reprogramming, reducing therapy efficacy [24].
MYC genes and proteins also interact with long non-coding RNAs (lncRNAs) by
regulating various cellular pathways and processes in cancer. Notably, lncRNAs have
recently been revealed to target MYC genes and proteins by regulating either MYC tran-
scription, protein stabilisation, activity, or other molecules involved in MYC expression
and activity [32,33]. As we will discuss later in this review, the interaction between MYC
and lncRNAs can be complex and fundamental to cancer progression via the regulation of
numerous processes, such as proliferation, survival, migration, and invasion.
MYC TFs have also been found to have a central role in cancer by inducing autophagy.
For instance, cells following transformation induced by MYC activated autophagy due
to mitochondrial stress, inhibiting tumour growth in vitro and in vivo [34]. This study
demonstrated that MYC-mediated transformation sensitised cells to autophagy induction
by the linamarase/linamarin/glucose oxidase system (lis/lin/GO), which activated the
AMPK pathway and upregulated autophagy genes [34–36]. These studies revealed a
central role for MYC-mediated cellular functions, signalling, and metabolic pathways.
In this review, we address the role of MYC as a transforming oncogene in multiple
cancers and how MYC is influenced by lncRNAs and may be implicated in crucial pro-
survival cellular processes such as autophagy. Finally, we discuss both these aspects
of MYC pathology to identify novel therapeutic strategies that may be implemented to
effectively establish MYC as a valid candidate for onco-therapy.
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2. Cancers with MYC-Related Functions in Their Pathogenesis
2.1. Prostate Cancer
MYCN is not usually expressed in the epithelial lineage that gives rise to prostate can-
cer. However, its aberrant expression can, in part, drive neuroendocrine prostate features in
advanced prostate cancer by epigenetic reprogramming [24]. A study aimed at understand-
ing the MYCN-triggered epigenetic reprogramming of prostate cancer to neuroendocrine
prostate fate, the cistrome, and the transcriptome of these tumours were investigated
in vitro, in vivo, and in patient-derived organoids. Genetically modified mice, Pb-Cre+/−
Ptenfl/fl LSL-MYCN+/+, develop prostate tumours in 100% of offspring compared with
littermates that lack MYCN expression (Pb-Cre+/− Ptenfl/fl LSL-MYCN−/−). In response
to castration, Pb-Cre+/− Ptenfl/fl LSL-MYCN+/+ mice developed invasive tumours with
metastatic features including epithelial-to-mesenchymal transition (EMT) (e.g., indicated
by vimentin expression) and the expression of neural markers (e.g., NCAM1) [24]. Fur-
thermore, transcriptional profiling of MYCN-expressing 22Rv1 prostate cancer xenograft
models in castrated and non-castrated states revealed that castration led to an increase in
expression of neural lineage genes (e.g., SOX11). This observation was also confirmed in
LNCaP-MYCN overexpressing cell lines, in which androgen absence led to the differential
expression of over 40% of MYCN target genes (including stem cell and neural lineage
differentiation markers). Contrastingly, in the presence of androgen, androgen receptor
(AR)-related genes were preferentially expressed [24]. Consistent with the acquisition of an
alternative identity, for LNCaP-MYCN expressing cell lines, the MYCN-driven cistrome
was revealed to be AR-dependent. In the presence of androgen, MYCN co-occupied ge-
nomic loci with targets of AR, including FOXA1 and HOXB13. In the absence of androgen,
the MYCN cistrome was diverted towards promoters of neural stem cell (NSC) genes. In
conclusion, MYCN-driven prostate tumours displayed greater aggressiveness, with MYCN
driving transcriptional programmes in advanced stages of prostate cancer [24,37].
2.2. Pancreatic Ductal Adenocarcinoma
In pancreatic ductal adenocarcinoma (PDAC) originating from exocrine acinar cells,
acinar to ductal metaplasia and progression to high-grade neoplasia were instigated upon
acquiring Kras mutations [25]. Kras mutant tumours maintained metabolic reprogramming
mediated by Myc and increased glycolytic flux and glutamine metabolism to meet the
energetic demands of elevated proliferation and redox maintenance, respectively [37]. Yap,
a transcriptional regulator, acted as a driver of Kras-mediated PDAC initiation [38], while
the roles of Myc, Yap, and Kras mutations in the maintenance of PDAC were investigated
using conditional transgenic mouse models. KrasG12D and Yap were sequentially activated
or deleted using Flp-FRT and tamoxifen-inducible Cre-lox systems, respectively (i.e., FSF-
KrasG12D/+, R26FSF-CreER/dual, Yapflox/flox, and pdx1-Flp) [25]. From a metabolic standpoint, the
co-expression of Yap and Myc promoted metabolic gene expression, leading to tumour
growth, maintenance, and survival in PDAC [25]. Furthermore, in partnership with TEA
domain (TEAD) TFs, Yap promoted Myc transcription and cooperated with Myc in regu-
lating metabolic gene expression. The ablation of Yap led to a metabolic crisis, regression
of tumours at early stages, and cell death. Interestingly, in the absence of Yap, Myc ex-
pression levels were upregulated by Sox2, resulting in a reversal of the inhibitory effect
of Yap deletion on cell proliferation and metabolic gene regulation. This compensatory
effect ultimately led to the re-differentiation of neoplastic ductal cells to acinar cells with
associated pancreatic enzyme production, highlighting the complexity of MYC-driven
metabolic networks [25].
2.3. Medulloblastoma
Medulloblastoma is an aggressive paediatric brain tumour classified into the WNT,
SHH, group 3, and 4 subtypes. In subgroup 3 of this cancer, somatic MYC alterations and
amplifications have been reported, although it remains unclear whether these alterations
alone drive tumourigenesis [26]. In a study aimed at understanding the contribution of
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MYC to malignant transformation, lentiviral MYC was transduced into unsorted mouse
cerebellum cells, which were subsequently orthotopically transplanted into NOD SCID
gamma (NSG) mice, leading to tumour formation. This study also revealed that Sox2 was
required for tumour initiation since the co-expression of endogenous Sox2 with transduced
MYC was sufficient to lead to tumourigenesis in vivo [26]. This study also demonstrated
that the Sox2+ cell population expressing Aldh1a1, a protein associated with a cancer stem
cell phenotype, generated tumours in vivo, while this capacity decreased with lower or
absent expression of Aldh1a1 [26]. Additionally, the expression of lactate dehydrogenase A
(LDHA) positively correlated with MYC expression levels indicative of an unfavourable
prognosis in this medulloblastoma subtype [26]. The inhibition of LDHA in vivo led
to reduced growth of MYC-driven tumours but not MYC-independent tumours [26].
In conclusion, this study revealed that MYC-induced transformation of Sox2+/Aldh1a1high
cells led to tumour growth in the postnatal cerebellum in vivo, with characteristics of type
3 medulloblastoma [26].
2.4. Neuroblastoma
Risk stratification for NBs is dependent on multiple variables, including MYCN am-
plification status and age [39]. Of these, MYCN amplification, seen in more than 50% of
high-risk NBs, is the strongest indicator of poor clinical prognosis. The mechanism by
which MYCN influences NB development was investigated in a study that analysed the
transcriptomic profile, specifically miRNA and mRNA interactions implicated in tumouri-
genesis, of premalignant sympathetic ganglia and tumours from tyrosine hydroxylase
promoter-driven MYCN (TH-MYCN+/+) transgenic mice [28]. For instance, mir-204 was
shown to suppress a network of oncogenes associated with MYCN, while mir-204 and
MYCN mutually repressed each other’s expression by binding to the corresponding pro-
moter, in association with relevant transcriptional machinery and repressors [28]. Through
this negative repression mechanism, the insertion of miR-204 mimics into MYCN amplified
NB cell lines led to a reduced colony-forming capacity. Accordingly, miR-204 was identified
as a tumour suppressor and a putative therapeutic agent, since in mouse xenograft exper-
iments, MYCN-amplified cells transduced with an inducible miR-204 construct showed
delayed tumourigenesis [28].
2.5. Colorectal Cancer
Deregulation of the Wnt-APC pathway can lead to increased levels of MYC in colorec-
tal cancer (CRC) [7]. The role of MYC in metabolic reprogramming of CRC was investigated
in a study by Satoh and colleagues in which they compared multi-omics profiles across
275 matched tumour and normal patient tissues. The upregulation of MYC was detected at
all stages of cancer progression and resulted in the aberrant regulation of 231 metabolic
genes involved in pathways including MAPK signalling, pentose phosphate, and fatty acid
metabolism [7]. Interestingly, the most remarkable changes to these metabolic genes, or a
metabolic shift, were detected at the adenoma stage and maintained in later stages of the
tumourigenic process. Interestingly, the knockdown of MYC in vitro led to a reversal of
the altered metabolism and reduced cell growth. This study provided evidence that MYC,
as a regulator of metabolic processes, governed the metabolic reprogramming of CRC by
regulating metabolic reactions and a multitude of genes involved in metabolism, such as
CAD, UMPS, and CTPS [7]. This finding may impact diagnostic studies.
2.6. Rhabdomyosarcoma
Over 40% of alveolar Rhabdomyosarcoma (RMS) show MYCN amplification associ-
ated with improved overall survival. MYCN expression is also characteristic of embryonal
RMS, although gene amplification is not a feature in this subtype [40–42]. In a study focused
on the mechanisms behind RMS tumourigenesis, immortalised human myoblasts express-
ing constitutive MYCN and doxycycline-inducible PAX3-FOXO1 (a fusion protein) were
grafted orthotopically to immunodeficient mice. Food supplementation with doxycycline
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led to the induction of PAX3-FOXO1 and the formation of RMS tumours. Cells transformed
exclusively with PAX3-FOXO1 generated tumours after a longer period of time than those
also expressing MYCN. These results suggest cooperation between these two TFs in the
early stages of tumourigenesis, leading to an increase in proliferation and the inhibition of
the myogenic differentiation programme [29]. Interestingly, the withdrawal of doxycycline
from animal diets after tumour formation led to tumour regression followed by tumour
recurrence, suggesting that, while RMS tumours are dependent on PAX3-FOXO1, these
may relapse through PAX3-FOXO1-independent pathways [29].
2.7. Non-Small Cell Lung Cancer
MYC and KRAS act as downstream conduits for other oncogenic drivers, enhancing
the process of tumourigenesis in lung adenomas and their transformation to invasive and
proliferative adenocarcinoma of the lung [30,31]. A study by Soucek and colleagues, focus-
ing on an endogenous Myc-switchable KrasG12D (LSL-Kras, TRE-Omomyc, and CMVrtTA)
mouse model of lung adenocarcinoma showed that KrasG12D expressing mice developed
bronchiolar hyperplasia [31]. The Kras-dependent bronchiolar hyperplasia regressed with
Omomyc expression, suggestive of a role for Myc in maintaining KrasG12D-driven lung
tumours. Mechanistically, Omomyc expression inhibited cellular proliferation by downregu-
lating Myc expression. Interestingly, Myc inhibition in normal, healthy tissues with a rapid
turnover, such as the epidermis, testis, and intestinal tract displayed reduced proliferation.
Despite these effects, the systematic suppression of Myc was tolerated since the reversal of
Myc inhibition led to rapid recovery of the affected tissues [31].
In a follow-up study using LSL-KrasG12DRosa26-LSL-MycERT2 transgenic mice, with
constitutive expression of KrasG12D and inducible expression of MycERT2, it was proposed
that, while the KrasG12D mutation alone was sufficient to induce preneoplastic lesions,
the additional activation of Myc led to rapid acceleration of tumourigenesis, hence trans-
forming indolent tumours to adenocarcinomas [30]. This group also investigated the
effect of MycERT2 activation on angiogenesis and the tumour microenvironment, revealing
that Myc governed processes such as inflammation and angiogenesis through its non-
cell-autonomous effectors, IL-23 and CCL9, which induce microenvironment alterations.
Consistently, the blockage of CCL9 alone led to the extensive inhibition of macrophage
influx mediated by Myc, loss of T cells, and the prevention of new blood vessel formation.
In contrast, the inhibition of IL-23 led to tumour cell death by apoptosis; a reduction in
proliferation; and the recruitment of B, T, and NK cells [30]. Ultimately, this study pointed
towards the marked capacity of Myc to suppress innate and adaptive immunity in tissues
and to induce adenocarcinomas from indolent tumours.
In summary, we reviewed MYC-driven regulatory networks in multiple cancers and
highlighted potential novel therapeutic axes involved in each specific cancer type. Due
to the difficulty in directly targeting MYC for therapy, these studies were invaluable and
could lay the groundwork for successful MYC-focused treatment strategies.
3. MYC and Long Non-Coding RNAs (LncRNAs) in Cancer
3.1. LncRNAs in Cancer as Novel Biomarkers and Therapeutic Targets
LncRNAs have been shown to interact with TFs, including MYC, often via direct
regulation of their expression, protein stabilisation, and activity or via indirect regulation
of other molecules involved in their expression and activity [32,33,43]. LncRNAs are non-
coding RNA (ncRNA) molecules longer than 200 nucleotides and are the most abundant
class of non-coding transcripts. LncRNAs are aberrantly expressed in several malignancies,
and both the lncRNAs and the mechanisms associated with the complex structures they
can form, allowing for their interaction with a large number and variety of molecules,
have been extensively studied in the context of cancer biology and treatment [33]. Notably,
lncRNAs are often expressed in a tissue- and disease-specific manner with critical functions
in several cancers and have great potential as novel biomarkers and therapeutic targets in
cancer [44–46]. Consistently, lncRNAs have been isolated from patient’s biological fluids,
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either free or packed into exosomes [47,48]. Clinical trials are currently recruiting patients
for lncRNA-based cancer diagnostics (URL: https://clinicaltrials.gov/ct2/show/NCT0
3830619) (accessed 15 February 2019); a trial focused on using serum exosomal lncRNAs
as putative biomarkers in lung cancer diagnostics. Other lncRNAs have already been
approved for clinical use; for example, PCA3 is currently used in the diagnosis of prostate
cancer [49]. Additionally, most lncRNAs are upregulated in specific oncogenic pathways,
and their inhibition could act alone or in combination with other treatments to improve
patient response. Several methods of lncRNA inhibition include antisense oligonucleotides
(ASOs), single-stranded DNA polymers, locked nucleic acids (LNA), and morpholinos
(Table 2) [50–56].
Table 2. Strategies to modulate MYC-driven gene networks concerning regulatory, lncRNAs, and autophagy-related
processes and networks.
Target Mechanism ofRegulation Outcome Malignancy
MYC Antisense oligonucleotidemorpholinos
Reduction of pro-angiogenic proteins
and metastasis Lung cancer [55]
linc00485/miR-298/MYC
network linc00485 silencing Reduction of cancer cell proliferation Lung cancer [57]
Linc00261/p300/CBP/MYC
network Linc00261 overexpression
Inhibition of cancer cell proliferation,
migration, and metastasis in vitro Pancreatic cancer [58]
LPP-AS2/miR-7-





Reduced cell growth in vitro and
in vivo NSCLC [60]
AMBRA1-PP2A/MYC
regulated by mTOR mTOR inhibition
MYC protein degradation and
reduction in cell proliferation








and tumour formation, Increase in
MYC-dependent apoptosis
Human P493-6B
lymphoblastoid cell line and
MEF cells [62]
CMA/ CIP2A/ MYC CMA activation Proteasomal degradation of MYC MEF cells [63]
3.2. Oncogenic IncRNAs Promote MYC Expression and Activity in Cancer
Several studies have focused on the roles of lncRNAs in MYC regulation in cancer; in
recent years, novel mechanisms and interactions that are of clinical relevance have been
characterised. One notable mechanism is the mutual regulation of lncRNAs and MYC via
intricate feedback loop mechanisms. LncRNAs are often upregulated in cancer and can pro-
mote oncogenic pathways and phenotypes. For example, a regulatory network modulated
by MALAT1 in thyroid cancer has shown that this lncRNA acts as a competing endogenous
RNA (ceRNA) by sequestering miR-204 (Figure 2A) [32]. In Figure 2A, MALAT1 and
miR-204 have been referred to as lncRNA and miRNA, respectively. Specifically, this study
revealed that, in thyroid cancer, MALAT-1 and insulin-like growth factor 2 mRNA binding
protein 2 (IGF2BP2), a member of RNA binding proteins, were expressed while mir-204
was expressed poorly. IGF2BP2 was identified as a target of mir-204 and the regulatory
loop comprising these players was identified as follows: MALAT1 selectively bound to
mir-204, preventing mir-204 from binding IGF2BP2 and leading to IGF2BP2 upregulation.
As a result, IGF2BP2 could recognise the N6-methyl-adenosine (m6A) modification of MYC
RNA and could consequently increase its expression. This regulatory network resulted
in increased proliferation, migration, and invasion of thyroid cancer cells [32]. Hence,
targeting lncRNAs may simultaneously affect numerous downstream oncogenic pathways,
including MYC, representing a valid therapeutic approach.
Linc00485 is another example of an oncogenic lncRNA for which expression is upregu-
lated in human lung cancer and is associated with metastasis and relapse [57]. Notably,
linc00485 was associated with the tumour-node-metastasis (TNM) stage in this cancer,
and linc00485 overexpression increased the proliferation, migration, and invasiveness of
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lung cancer cells by directly sequestering miR-298, which targeted MYC. The significance
of the linc00485/miR-298/MYC axis in vivo, demonstrated using xenotransplantation of
lung cancer cell lines including A549, revealed that linc00485 silencing using short hairpin
lincRNA resulted in reduced cancer cell proliferation. Collectively, this study showed a
crucial regulatory link involving MYC, miRNAs, and lncRNAs while offering a promising
therapeutic strategy (Table 2) [57].




Figure 2. Regulatory loops involving lncRNAs and MYC. (A) A lncRNA (e.g., MALAT1) acting as a competing endogenous 
RNA by sequestering miRNA (e.g., miR-204), allowing for the production of MYC. (B) The physical interaction between a 
lncRNA (e.g., linc00261) prevents the recruitment of p300/CBP to the promoter region of MYC, thereby repressing MYC 
expression. 
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RNA by sequestering miRNA (e.g., miR-204), allowing for the production of MYC. (B) The physical interaction between
a lncRNA (e.g., linc00261) prevents the recruitment of p300/CBP to the promoter region of MYC, thereby repressing
MYC expression.
Int. J. Mol. Sci. 2021, 22, 8527 9 of 20
3.3. LncRNAs Repress MYC under Certain Conditions
LncRNAs are not exclusively oncogenes and can also act as tumour suppressors in
specific circumstances. An example is linc00261, which acts as a tumour suppressor in
pancreatic cancer via transcriptional regulation of MYC expression. Linc00261 directly
binds to the bromodomain of the transcriptional co-factor p300/CBP (a member of the tran-
scriptional co-activator family), preventing its recruitment to the promoter region of MYC,
thereby epigenetically repressing MYC expression (Figure 2B, linc0026 is lincRNA) [58].
Finally, linc0026 overexpression inhibited pancreatic cancer cell proliferation, migration,
and metastasis in vitro (Table 2) [58].
An alternative mechanism of linc00261 activity in pancreatic cancer is via targeting
of miR-222-3, leading to the modulation of MYC expression both via miRNA regulation
and sequestration of insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1).
Mechanistically, linc00261 was downregulated by methylation of the CpG islands (regions
of DNA with greater CG content) associated with its promoter, and the enhancer of Zeste
2 Polycomb repressive complex 2 subunit (EZH2) mediated the methylation of lysine 27 of
histone 3 (H3K27) (also known as permissive histone marks) deposited to its promoter
region. This suggests a complex interaction between lncRNAs and epigenetics in the
regulation of oncogenes such as MYC [58,64].
Another example, PVT1 lncRNA, was a regulator of the transcription of key oncogenic
pathways, such as TGFβ/SMAD and Wnt/β-catenin, acting as an enhancer for MYC [65].
Specifically, the PVT1 locus impacted the expression of essential genes in both pathways
while the aberrant methylation of PVT1 lncRNA also led to alterations in MYC expression.
Therefore, it is not surprising that the PVT1 lncRNA expression was associated with a poor
prognosis for CRC patients [65].
On the contrary, in lung adenocarcinoma, the PVT1b isoform is expressed downstream
of MYC and is induced by DNA damage and oncogenic signals, thus acting as a tumour
suppressor [66]. Once transcribed, PVT1b accumulated near the MYC transcription start
site, contributing to the suppression of MYC expression in cis, a mechanism triggered by
P53 [66]. It follows that PVT1b inhibition resulted in an escalation of MYC expression
and activity, leading to an increase in cell proliferation; indeed, loss of PVT1b in vivo
promoted tumour growth [66]. In conclusion, the P53-induced lncRNA-mediated changes
in transcription may allow for rapid adaptation and response to cellular stress.
3.4. Mutual Regulation of IncRNAs and MYC via Feedback Loops
LncRNA-MYC feedback loop mechanisms have been studied in different malignancies
with biological and clinical relevance to cancer phenotypes. An interesting example may
be metastasis suppressor 1 (MTSS1) and its lncRNA. In pancreatic cancer, the lncRNA
MTSS1-AS upregulated its sense gene, metastasis suppressor 1 (MTSS1), by acting as a
scaffold/decoy between E3 ubiquitin-protein ligase STIP1 homology and U-box containing
protein 1 (STUB1), which earmarks proteins for proteasomal degradation and the tran-
scription regulator myeloid zinc finger 1 (MZF1). MZF1 inhibited MTSS1 expression by
binding its promoter (Figure 3A, MTSS1-AS, MTSS1, and MZF1 are lncRNAs encoded
by gene A-AS, gene A, and regulatory protein, respectively), and MTSS1-AS-induced
ubiquitination-mediated degradation of MZF1 leads to the upregulation of MTSS1 [67].
Furthermore, extracellular acidity reduced MTSS1-AS levels, thereby stabilising MZF1 and
promoting metastasis [67].
MYC regulation was upstream of this pathway, and MYC binds the initiator elements
of the MTSS1-AS promoter, thereby inhibiting lncRNA transcription in association with
relevant transcriptional machinery [67]. In turn, MTSS1-AS repressed the MZF1-mediated
transcription of MYC, thereby forming a negative feedback loop between MTSS1-AS and
MYC in acidic pancreatic cancer cells, with overexpression or knockdown of MTSS1-
AS leading to the inhibition or promotion of MYC expression, respectively (Figure 3B,
MTSS1-AS, MTSS1, and MZF1 are lncRNAs encoded by gene A-AS, gene A, and regulatory
protein, respectively).
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Finally, lncRNA-MYC feedback loops inc uded LPP ant sense RNA-2 (LPP-AS2), a
lncRNA hat was fou d to be upregulated in glioma. Specifically, LPP-AS2 sequestered mir-
7-5p, thereby increasing the expressio of EGFR and the downstream PI3K/AKT/MYC axis,
promoti g the transcription of MYC, via is positiv feedbac l op. In turn, MYC bound
directly to the promoter of LPP-AS2 [59]. Depletion of the LPP-AS2/miR-7-5p/EGFR/MYC
axis reduced glioma cell proliferation and i vasion, and triggered apoptosis. In vivo
LPP-AS2 knockdown inhibited tumour growth, whereas LPP-AS2 overexpression had the
opposite effect [59]. The oncogenic activity of LPP-AS2 in this positive feedback loop may
be a target for therapeutic interventions (Table 2) [59].
To summarise, we reviewed the regulatory complexity surrounding the circuits com-
prising of MYC and various lncRNAs, miRNA, and signalling pathways. LncRNAs can act
as oncogenes by increasing MYC expression and activity or by inhibiting MYC expression.
This regulation of MYC function is dependent on multiple positive and negative feedback
loops. The enhanced understanding of these regulatory networks could pave the way to
the effective targeting of MYC-driven regulatory networks and could introduce lncRNAs
as novel biomarkers in cancers and putative therapeutic targets.
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4. MYC and Autophagy
4.1. MYC, Autophagy, and Cellular and Molecular Processes in Cancers
Macro-autophagy, hereafter referred to as autophagy, is a major degradation pathway
for many organelles, toxic aggregates, and long-lived proteins. In this process, fractions of
the cytoplasm are engulfed in a double-membrane structure, also known as an autophago-
some. This structure is then fused with lysosomes, allowing for the degradation of its
content. MYC, along with other genes such as mTOR, Beclin-1, p53, PTEN, p62, MIF, HMGB1,
RAC3, SRC3, NF-2, MEG3, LAPTM4B, and BRAF play essential roles in autophagy-induced
tumourigenesis and drug resistance, a new focus of drug development efforts [68]. Toh
and colleagues showed that MYC was involved in autophagosome formation in the early
stages of autophagy rather than in its degradation and that MYC-driven modulation of
autophagy occurs via the JNK1-Bcl2 pathway and ROS (Figure 4). The siRNA-mediated
knockdown of MYC inhibited autophagy in human embryonic kidney (HEK293) cells,
resulting in an accumulation of the autophagy substrate p62 (SQSTM1/sequestome1, an
autophagy receptor, and signalling adapter). Hence, MYC inhibition led to defective au-
tophagosome formation and reduced the clearance of essential autophagy substrates [69].
This study pointed towards the additional benefit of MYC modulation on autophagic
processes, especially in autophagy-induced therapy resistance.
Moreover, MYC-induced alterations in autophagy can impact tumourigenesis, whereby
the dysfunction of MYC-mediated autophagy contributed to non-small cell lung cancer
(NSCLC) development [60]. In NSCLC, inhibiting MYC/miR-150 expression greatly re-
duced cell growth in vitro and in vivo (Table 2) [60]. In miR-150 overexpressing cell lines, a
dysfunction in autophagic flux was observed, as shown by higher numbers of autophago-
somes and lower numbers of autolysosomes. miR-150 inhibited the fusion of autophago-
somes and lysosomes by directly repressing EPG5, a gene essential for autophagosomal
maturation, consequently promoting NSCLC development. Since autophagy deficiency
caused the accumulation of damaged mitochondria, it was not surprising that ROS levels
were increased in miR-150 overexpressing A549 and H1299 NSCLC cells [60].
In parallel with the aforementioned reports, numerous studies have alluded to the
association of multiple factors with the autophagic processes that may affect MYC protein
stabilisation. Noteworthily, MYC protein stability is defined by the interaction between
two phosphorylation sites, serine 62 and threonine 58 (by ERK and glycogen synthase
kinase-3β, GSK3β, respectively). Serine 62 phosphorylation leads to MYC stabilisation
but promotes the phosphorylation of threonine 58, destabilising the protein [70]. Here, we
focus on two examples.
In osteosarcoma, polo-like kinase 1 (PLK1, a serine/threonine protein kinase) and
MYC promote cell proliferation through the autophagic pathway [71]. PLK1, a protein
kinase, is a major driver of proliferation and growth that correlated with poor prognosis
when expressed in this cancer. The knockdown of MYC led to decreased LC3-II/LC3-I
(standard markers of autophagosomes) and autophagy-related protein 7 (Atg7) as well
as defects in autolysosomal degradation. Similarly, the knockdown of PLK-1 resulted in
significantly decreased autophagy markers, such as LC3-II/LC3-I and Atg5, in parallel
with SQSTM1 accumulation and defects in the autolysosomal pathways. Moreover, PLK-1
contributed to MYC protein stabilisation while PLK1 inhibition led to a significant loss of
MYC abundance. Consequently, this caused a marked delay in xenograft tumour growth in
mice treated with the PLK-1 inhibitor BI2536, with a lower mean tumour volume compared
with the control group [71].
Another protein with a role in autophagy initiation is AMBRA1, a scaffold protein
that is a downstream target of mTOR, a major regulator of autophagy. This protein
was found to play a tumour suppressor role by promoting MYC dephosphorylation and
degradation in lung and breast cancer cell lines. Disruption of the Ambra1 locus induced
MYC hyperphosphorylation, leading to tumour hyperproliferation and tumourigenesis.
Moreover, when mTOR was inhibited, AMBRA1 enhanced the interaction between MYC
and its phosphatase PP2A, consequently reducing cell proliferation (Table 2) [61]. From
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these studies, it is possible to put forth PLK1 and AMBRA1 as valuable candidates for
therapies aimed at targeting MYC protein stability.
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Figure 4. MYC and autophagy. MYC was involved in autophagosome formation whereby siRNA-mediated knockdown
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In addition to the examples above, MYC may also be associated with the pathway con-
necting the endoplasmic reticulum (ER) stress and autophagy. Hart and colleagues showed
that ER stress-mediated autophagy stimulated MYC-dependent transformation and tumour
growth. Specifically, they showed that MYC and MYCN activated the PERK/eIF2α/ATF4
arm of the unfolded protein response (UPR) (one of the three arms of UPR) in the P493-6
human lymphoblastoid cell line and mouse embryonic fibroblast (MEF) cells, resulting in
increased cell survival via the induction of autophagy (Table 2) [62]. The inhibition of PERK
led to reduced MYC-induced autophagy and a significant decrease in tumourigenesis,
while the inhibition of autophagy increased the level of apoptosis in an MYC-dependent
manner. Blocking ER stress was sufficient to restore normal levels of protein synthesis and
consequently reduced autophagy. This link between UPR, ER stress, and autophagy may
provide an attractive therapeutic target [62].
4.2. Chaperone-Mediated Autophagy (CMA) and Mitophagy Link with MYC
MYC has also been linked with another form of autophagy, chaperone-mediated
autophagy (CMA), a selective form of protein lysosomal degradation (Table 2). In most
cancers, CMA is upregulated and is essential for tumour growth [72]. Kon and colleagues
revealed a novel tumour-suppressor role for CMA in MEF cells, where CMA inhibited the
oncogenic activity of MYC by promoting its proteasomal degradation. Mechanistically,
CMA triggered MYC destabilisation by regulating CIP2A degradation. CIP2A inhibited
a phosphatase that dephosphorylated MYC at Ser62, preventing the ubiquitination and
subsequent degradation of MYC (Table 2). Naturally, blocking CMA led to reduced
degradation of CIP2A and increased stability of MYC, acting a as potential preventative
strategy in cancer initiation (Figure 5, CIP2A is referred to as a regulatory protein) [63].
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Consistently, other studies have shown a link between MYC and mitophagy, a process
of selective degradation of mitochondria by autophagy following stress or damage [73]. The
mild and sustained hydrogen peroxide treatment induced P rkin-mediated mitophagy and
reduced the accumulation of GSK3β in the nucleus, thus decreasing the phosphorylation
of MYC. The levels of miR-106b-93-25 cluster, which was downstream from MYC, were
elevated, and this cluster inhibited the mitophagy-associated proteins (e.g., OPTN) to
protect against excessive mitophagy, ultimately leading to cell death due to bioenergetic
collapse [74,75]. This suggested that miRNAs targeting mitophagy-associated proteins
were essential for cell survival a d were a mechanism of mitophagy control.
A connecting piece of the puzzle is the link between mitophagy, autopha y, and a
membrane protein. A study of MYC-driven lymphomagenesis found that Bax-interacting
factor 1 (Bif-1), a member of the membrane curvature-driving endophilin protein family,
also known as SH3GLB1, plays a role in apoptosis, autophagy, and mitophagy [76]. Bif-1
was found to play a crucial role in the maturation of nascent autophagosomes during
mitophagy to maintain chromosomal stability [76]. Bif-1 haploinsufficiency in the Eµ-MYC
mouse model (a widely used model of MYC-driven malignancy) accelerated MYC-driven
lymphomagenesis by suppressing mitophagy and resulted in increased mitochondrial mass
within cells at the premalignant state of MYC-induced lymphoma. Since the accumulation
of damaged mitochondria (by suppressing autophagy) led to ROS generation and DNA
damage accumulation, improper mitochondrial clearance was likely the mechanism behind
the promotion of chromosomal instability induced by the loss of Bif-1 in MYC-induced
lymphoma [76].
In summary, in this secti n, we discussed the interplay between MYC regulatory
networks with crucial cellular and molecular processes. We reviewed that MYC was in-
volved in autophagosome formation. Moreover, MYC functional alterations in autophagic
processes could contribute to tumourigenesis. We also revealed the role of multiple proteins
affecting MYC protein stability. Finally, we investigated UPR, CMA, and mitophagy as
cellular processes that may impact MYC functions and stability.
5. Discussion: Novel Treatment Options for MYC-Driven Malignancies in Light of the
Topics Discussed
Chemotherapy has been instrumental in the treatment of MYC-driven cancers. How-
ever, a major caveat with these approaches is the non-discriminatory targeting of prolif-
Int. J. Mol. Sci. 2021, 22, 8527 14 of 20
erating cells triggering widespread off-target effects. Thus, these methods are gradually
replaced by more targeted and effective treatment modalities that rely on the specific
targeting of factors that lead to the tumour’s initiation, propagation, and progression. One
example of this is the notion of “oncogene addiction”, whereby, in theory, the genetic
inhibition of oncogenes such as MYC is sufficient to cause cell death and reduced tumour
burden. Additionally, due to the role of this oncogene in development, regulatable trans-
genic systems have been critical to these observations, allowing for a better understanding
of the effects of de novo activation or inactivation of MYC [77]. For instance, in the context
of preclinical mouse models, transcriptional activation of MYC in an inducible c-MycER™
mouse model of the epidermis resulted in papillomatosis, blood vessel formation, apopto-
sis, and precancerous lesions. Inversely, the lesions regressed upon tamoxifen removal and
MYC inactivation [77]. This observation supported the idea that transient inactivation of
an oncogene such as MYC can be considered a viable therapeutic strategy.
The regulation of MYC can also be achieved on a transcriptional level whereby the
BET bromodomain protein, BRD4, interacts with the positive elongation factor complex
b (p-TEFb), which is regulated by MYC [78]. Therefore, the BET bromodomain inhibitor,
JQ1, was studied in multiple myeloma (MM) for its capacity to inhibit MYC-dependent
transcription. In MM, the rearrangement of MYC via a translocation is a frequently occur-
ring genetic alteration while the activation of MYC can be observed in over half of MM
cases [79]. In a panel of MM cell lines, JQ1 treatment led to an increase in cells arrested
in the G0/G1 phase of the cell cycle and cellular senescence (marked by B-galactosidase
expression). Still, only modest levels of apoptosis were detected [79]. In an orthotopic
mouse xenograft model, JQ1 treatment led to a decreased disease burden and increased
overall survival of these mice compared to controls [79]. Furthermore, MYC-dependent
processes such as glycolysis were also affected by JQ1. Collectively, these results pointed
towards the feasibility of specifically targeting MYC and its extensive targets [79].
On a different note, MYC protein can also be modulated by various molecules [43,80].
For example, the interaction between lncRNA LUCAT1 and Nuclein (NCL, an inhibitor
of MYC) is interesting. LUCAT1 interacted with NCL via its G-quadruplex structure (a
structure formed by guanine rich nucleic acids) in CRC and promoted MYC expression
and cancer cell proliferation. Interestingly, in knockdown and rescue experiments, cells
lacking LUCAT1 displayed reduced MYC levels, while this phenotype could be rescued by
NCL knockdown [80].
Furthermore, it has proven possible to target MYC with morpholinos in lung and
prostate cancers; the latter has been tested successfully in preclinical models and clinical
trials [55,56]. Notably, morpholinos and other ASOs have been studied as successful
approaches to target lncRNAs, some of which are regulated by or regulate MYC and can
also be correlated with MYC via mutual modulation of expression and function [59,67,81].
Since lncRNAs can be upregulated under specific pathological conditions, the indirect
targeting of MYC oncogenic functions via direct targeting of lncRNAs should, in principle,
lead to improved treatment efficacy and reduced side effects. In this context, lncRNA-
mediated upstream regulation of MYC should be further investigated, such as modulation
of the MALAT1/mir-204 axis in thyroid cancer, which, as reviewed in Section 3.1, could be a
plausible method of reducing levels of MYC. We reviewed that MALAT1 increased IGF2BP2
and MYC expression by binding to mir-204 [32], a process that can be manipulated as a
therapeutic strategy by inhibiting MALAT1 or increasing mir-204 levels. Other lncRNAs
such as linc00261, linc00485, and LUCAT1 may also show potential for regulating MYC
levels and tumour-associated functions via their modulation [43,57,58].
MYC-driven gene regulatory networks also apply to the axis of miRNA and autophagy
networks and, hence, may be exploited for treatment. For example, the involvement of
miR-27b-3p in MYC-induced autophagy was investigated in CRC. In this study, CRC cells
became resistant to oxaliplatin (OXA) through the MYC/miR-27b-3p/ATG10 axis [82].
This study found that MYC, in association with relevant transcriptional machinery and
repressors, repressed the transcription of miR-27b-3p, upregulating autophagy and leading
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to chemoresistance. Furthermore, miR-27b-3p, upon inhibiting autophagy, resensitised
chemoresistant CRC cells to OXA through Atg10 suppression. Indeed, siRNA-mediated
ATG10 suppression inhibited the proliferation of SW480 colon adenocarcinoma cells and
resensitised them to OXA [82]. Perhaps the most exciting finding of this study was the
dissection of the MYC/miR-27b-3p/ATG10 axis for therapy [82].
In line with the significance of various autophagic pathway components, includ-
ing lysosomes in the completion of autophagy, lysosomal protein transmembrane 4 beta
(LAPTM4B), a potential oncogene was investigated with respect to MYC regulatory net-
works in breast cancer [83]. For instance, LAPTM4B was shown to play a critical role in
tumour proliferation; metastasis; autophagy inhibition; and resistance to chemotherapeu-
tic drugs such as doxorubicin, cisplatin, and paclitaxel [83]. LAPTM4B-35 (the protein
product) activated the PI3K/AKT signalling pathway leading to the phosphorylation of
GSK3β, resulting in the attenuation of MYC degradation and consequently promoting the
proliferation of carcinoma cells [84]. This significant finding suggested that LAPTM4B-35
may be an attractive target for reducing MYC levels. Additionally, the downregulation of
LAPTM4B-35 by RNAi decreased the efflux of chemotherapeutic agents, hence sensitising
chemical therapy [84]. These studies have brought together MYC regulatory networks,
lysosomal proteins, drug resistance, and autophagy as drug therapy candidates.
Finally, in addition to autophagy, the interaction of MYC with mitophagy and cellular
metabolism was a focus of our review and may provide valuable biomarkers and thera-
peutic approaches in cancers. For instance, for diffuse large B-cell lymphoma (DLBCL),
MYC induces abnormal choline metabolism by transcriptionally activating the essential
gene, phosphate cytidylyltransferase 1 choline-α (PCYT1A), a gene involved in the syn-
thesis of phosphatidylcholine [85]. The lipid-lowering alkaloid Berberine (BBR) exhibited
anti-lymphoma activity by inhibiting MYC-driven PCYT1A expression and by activat-
ing mitophagy-dependent necroptosis, both in vitro and in vivo. B-cell lymphoma cell
necroptosis was reversed by treatment with the mitophagy inhibitor Mdivi-1 [85]. This
study revealed that the effective manipulation of MYC requires an understanding of the
meshwork of cell death and survival, and autophagic and mitophagy processes.
In conclusion, the effective (in)direct targeting of MYC TFs through their regulatory
networks with cellular and molecular networks in MYC-driven malignancies has shown
promising potential for cancer therapy over traditional methods. In this review, we dis-
sected numerous MYC networks associated with lncRNAs, autophagy, and mitophagy,
in which specific targeting of MYC was achieved on transcriptional, epigenetic, miRNA
regulation, or protein levels. These interactions and mutual regulations could be viewed as
unexplored areas of MYC targeting that may warrant a more in-depth investigation with
the objective of future clinical implementation. These strategies are in line with reducing
off-target effects of non-specific and non-context-specific targeting of these TFs in the
broader context of physiological and pathological networks and processes.
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bHLHZip basic helix-loop-helix leucine zipper
Bif-1 Bax-interacting factor 1
BRD4 BET bromodomain protein 4
ceRNA competing endogenous RNA
EZH2 Enhancer of Zeste 2 Polycomb repressive complex 2 subunits
CMA Chaperone-mediated autophagy
CRC colorectal cancer cells
DLBCL diffuse large B-cell lymphoma
EGF epidermal growth factor
EMT epithelial-to-mesenchymal transition
ER endoplasmic reticulum
GSK3β glycogen synthase kinase-3β
GRNs Gene Regulatory Networks
H3K27 Histone 3 lysine 27
HEK293 cells human embryonic kidney cells
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1
IGF2BP2 insulin-like growth factor 2 mRNA binding protein 2
LAPTM4B lysosomal protein transmembrane 4 beta
LDHA lactate dehydrogenase A
Lis/lin/GO linamarase/linamarin/glucose oxidase system
LNAs locked nucleic acids
LncRNAs long non-coding RNAs
LPP-AS2 LPP antisense RNA-2
M6A N6-methyl-adenosine
MEF murine embryonic fibroblast
MM multiple myeloma
MTSS1 metastasis suppressor 1




NCS neural stem cell
NSCLC non-small cell lung cancer
NSG NOD SCID gamma mice
OXA Oxaliplatin
PCYT1A phosphate cytidylyltransferase 1 choline-α
P-TEFb positive elongation factor complex b
PDAC pancreatic ductal adenocarcinoma
PLK1 polo-like kinase 1
RMS Rhabdomyosarcoma
ROS reactive oxygen species
SHH Sonic Hedgehog
STUB1 STIP1 homology and U-box containing protein 1
TCF/LEF T-cell factor/ lymphoid enhancer factor
TEAD TEA domain transcription factor
TF transcription factors
TGF-β transforming growth factor β
TH tyrosine hydroxylase
TNM tumour-node metastasis
UPR unfolded protein response
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